Jiangsu Nhwa Pharmaceutical Co., Ltd.
002262
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 19.57 | -9.17% |
| 2024 | 21.55 | -19.14% |
| 2023 | 26.65 | -2.96% |
| 2022 | 27.46 | 38.94% |
| 2021 | 19.77 | -10.89% |
| 2020 | 22.18 | 24.98% |
| 2019 | 17.75 | 5.87% |
| 2018 | 16.76 | -52.29% |
| 2017 | 35.14 | -17.43% |
| 2016 | 42.55 | -21.49% |
| 2015 | 54.20 | 24.07% |
| 2014 | 43.68 | -16.62% |
| 2013 | 52.39 | 43.72% |
| 2012 | 36.45 | 21.44% |
| 2011 | 30.02 | -42.07% |
| 2010 | 51.82 | 17.60% |
| 2009 | 44.06 | 48.83% |
| 2008 | 29.60 | -58.20% |
| 2007 | 70.82 | -10.00% |
| 2006 | 78.69 | 22.22% |
| 2005 | 64.38 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 78.61% |
IN
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.